BIOLASE, Inc. BIOL, the world's leading manufacturer and distributor of dental
lasers, announced today that the U.S. Food and Drug Administration
(FDA) has cleared the 940nm Diolase 10 diode soft tissue laser for
use in 19 additional medical markets including: ear, nose and throat,
oral surgery, arthroscopy, gastroenterology, general surgery,
dermatology, plastic surgery, podiatry, GI/GU, gynecology,
neurosurgery, ophthalmology, pulmonary surgery, cardiac surgery,
thoracic surgery, urology, dermatology, aesthetics, and vascular
surgery. This FDA clearance includes over 80 different procedures.
BIOLASE's diode lasers are used in dentistry for surgical soft tissue
procedures as an alternative to invasive and traumatic conventional
devices, such as the high-speed drill, scalpel or electrosurge. The
940nm wavelength is better absorbed by hemoglobin (Hb) and
oxyhemoglobin (HbO2) than other diode laser wavelengths(1), so it
cuts efficiently at low power and with considerably less heat and
discomfort, making it an excellent alternative to conventional surgical devices. BIOLASE's 940nm wavelength is also FDA cleared for
tooth whitening and temporary pain relief in a number of BIOLASE
products.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in